Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.49 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.49 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.49 |
| ▸ | ELANE | P08246 | 2/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43742 | 0.89 | KMT2A (0.61) | ALDH1A1KMT2AMAPTHTTLMNA | |
| SCHEMBL14276948 | 0.89 | PRSS1 (0.54) | ALDH1A1KMT2AMAPTHTTLMNA | |
| SCHEMBL30593894 | 0.87 | KMT2A (0.59) | ALDH1A1KMT2AMAPTHTTLMNA | |
| SCHEMBL17138135 | 0.86 | LMNA (0.52) | ALDH1A1KMT2AMAPTHTTLMNA | |
| SCHEMBL383482 | 0.86 | KMT2A (0.57) | ALDH1A1KMT2AMAPTHTTLMNA | |
| SCHEMBL5001696 | 0.84 | ALDH1A1 (0.81) | ALDH1A1KMT2AMAPTHTTLMNA | |
| SCHEMBL6554235 | 0.83 | KMT2A (0.55) | ALDH1A1KMT2AMAPTHTTLMNA | |
| SCHEMBL2058361 | 0.83 | ALDH1A1 (0.55) | ALDH1A1KMT2AMAPTHTTLMNA | |
| Di(Hydroxyethyl)Ether SCHEMBL12971202 | 0.83 | KMT2A (0.42) | ALDH1A1KMT2AMAPTHTTLMNA | |
| SCHEMBL23843934 | 0.82 | KMT2A (0.60) | ALDH1A1KMT2AMAPTHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113767097-B | Prodrugs of caspase inhibitors | 株式会社LG化学 | 2025-03-14 | — | — | CN | disclosed |
| US-12024549-B2 | Compound having affinity substance to soluble protein, cleavable portion and reactive group, or salt thereof | AJINOMOTO CO., INC. (JP) | 2024-07-02 | — | — | US | disclosed |
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | KLEO PHARMACEUTICALS, INC. | 2023-04-27 | — | — | US | disclosed |
| CN-104774607-B | The fluorescent probe of single-minded identification bivalent cupric ion and application in a kind of aqueous phase | 济南大学 | 2016-08-24 | — | — | CN | disclosed |
| CN-104774607-A | Fluorescent probe for specially identifying bivalent copper ions in water phase and application thereof | UNIV JINAN | 2015-07-15 | — | — | CN | disclosed |
| US-20070191263-A1 | Valency platform molecules comprising aminooxy groups | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2007-08-16 | — | — | US | disclosed |
| EP-1732876-A1 | PREPARATION OF LEVULINIC ACID ESTERS FROM ALPHA-ANGELICA LACTONE AND ALCOHOLS | E.I.Du pont de nemours and company (US) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005097724-A1 | PREPARATION OF LEVULINIC ACID ESTERS FROM ALPHA-ANGELICA LACTONE AND ALCOHOLS | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2005-10-20 | — | — | WO | disclosed |
| US-20050210738-A1 | Preparation of levulinic acid esters from alpha-angelica lactone and alcohols | E. I. DU PONT DE NEMOURS AND COMPANY | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191263-A1 | Valency platform molecules comprising aminooxy groups | DAO, PAM, BCAT2 | ALDH1A1 2138/4885KMT2A 457/4885MAPT 2550/4885 |
| US-20050210738-A1 | Preparation of levulinic acid esters from alpha-angelica lactone and alcohols | ADH1C, ADH1A, ADH5 | ALDH1A1 6/4885KMT2A 1284/4885MAPT 1918/4885 |
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | CD2BP2, CD2, CD47 | ALDH1A1 1047/4885KMT2A 310/4885MAPT 2513/4885 |
| US-12024549-B2 | Compound having affinity substance to soluble protein, cleavable portion and reactive group, or salt thereof | SPPL2B, CSTB, SPPL2A | ALDH1A1 1832/4885KMT2A 2873/4885MAPT 4288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.